Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
TileBio, a spin-out from the University of Glasgow, has raised £1.6M in seed funding led by Twin Path Ventures to develop AI technology for cancer diagnosis.
TileBio has secured £1.6M in seed investment to launch AI technology focused on cancer diagnosis and treatment. The funding will support AI model training, clinical validation studies, and team expansion. Investors include Twin Path Ventures, Scottish Enterprise, and GU Holdings Ltd. The aim is to create one of the largest pathology foundation models globally using real-world clinical data.
Company Information
Company
TileBio
Location
Glasgow, Scotland, United Kingdom
About
TileBio is a spin-out company from the University of Glasgow focused on developing AI technology to improve cancer diagnosis and treatment. The company has created a platform that enables AI systems to learn from millions of unlabelled medical pathology images, enhancing the speed and accuracy of diagnoses. With a long-term goal of creating one of the largest pathology foundation models globally, TileBio leverages large-scale clinical data to drive innovation in medical AI.
GlasgowBiotechnologyHealth CareArtificial IntelligenceMedicalMachine LearningHealth Diagnostics